PHN — Pharmanutra SpA Income Statement
0.000.00%
- €469.47m
- €475.92m
- €115.50m
- 95
- 18
- 30
- 42
Annual income statement for Pharmanutra SpA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 56.4 | 68.1 | 82.7 | 100 | 115 |
| Cost of Revenue | |||||
| Gross Profit | 53.7 | 65.8 | 79.9 | 97.8 | 109 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 43.2 | 49.4 | 59.7 | 76.8 | 88.1 |
| Operating Profit | 13.2 | 18.7 | 23 | 23.4 | 27.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 13.3 | 18.8 | 23.4 | 23.3 | 27.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 14.1 | 13.8 | 15 | 12.8 | 16.6 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 14.1 | 13.8 | 15 | 12.8 | 16.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 14.1 | 13.8 | 15 | 12.8 | 16.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.48 | 1.42 | 1.56 | 1.34 | 1.75 |
| Dividends per Share |